PTEN and neoplasm: In the cohort of patients with available tumor tissue and who provided consent, 24% (65/274) had tumors harboring PIK3CA mutations (E542K, E545K/D, and H1047R); 13% (49/390) of patients with available tumor tissue had absence of PTEN expression and 53% (205/390) had low PTEN expression.